Clinical trials: Epithelial-Mesenchymal Transition
Barrett's Esophagus, Gastroesophageal Reflux Disease
Reflux-Induced Oxidative Stress in Barrett's Esophagus: Response, Repair, and Epithelial-Mesenchymal-Transition
The purpose of this study is to elucidate mechanisms whereby oxidative stress induced by acute reflux esophagitis: 1) activates p38 to regulate proteins that control the G1/S cell cycle checkpoint, and 2) activates HIFs (hypoxia…
- Trial name
- NCT02579460
- Testing
- Cessation of Acid Suppressing Medications
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Dallas VA Medical Center
Peri-implantitis
Expression of Epithelial-Mesenchymal Transition Associated Markers in Peri-implant Tissues
Peri-implantitis is an inflammation of bacterial etiology characterized by inflammation of mucous membranes and bone loss around the dental implant.
- Trial name
- NCT05832541
- Where
- Iraq
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Baghdad
Non-small Cell Lung Cancer
Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC
This study was planned to determine if neoadjuvant capmatinib could improve the major pathological response (MPR) in patients with Stage IB-IIIA, N2 and selected IIIB (T3N2 or T4N2) lung cancers with Mesenchymal Epithelial…
- Trial name
- Geometry-N (NCT04926831)
- Testing
- capmatinib
- Where
- 6 sites in United States
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Triple Negative Breast Cancer, Chemotherapy Effect
The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer
Introduction: Most cases of Triple Negative Breast Cancer (TNBC) have a high proliferation rate. TNBC is associated with a poor prognosis, a high recurrence rate, and a high incidence of distant metastases.
- Conditions
- Triple Negative Breast Cancer, Chemotherapy Effect, Simvastatin Adverse Reaction
- Trial name
- NCT05550415
- Testing
- Simvastatin 40mg
- Where
- Indonesia
- Volunteers
- 26 people
- Sponsor
- Universitas Indonesia
NSCLC, Stage I, II, IIIA, IIIB, Surgery
Pronostic and Predictive Value of EMT in Localized Lung Cancer
The goal of the present research is to identify an "EMT signature", associated with long term disease-free survival after surgery in NSCLC.
- Conditions
- NSCLC, Stage I, II, IIIA, IIIB, Surgery, Progression, Epithelial Mesenchymal Transition
- Trial name
- TWISTlung (NCT03509779)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- European Georges Pompidou Hospital
Periodontitis
Impact of Guided Biofilm Therapy on Epithelial and Mesenchymal Biomarkers in Periodontitis Patients
The goal of this clinical trial is to investigate the clinical and biochemical effects of the guided biofilm therapy protocol as an alternative to the conventional non-surgical periodontal therapy in patients with periodontitis.
- Trial name
- NCT07286916
- Testing
- Root surface debridement, Guided Biofilm Therapy
- Where
- Iraq
- Volunteers
- 18 people
- Sponsor
- University of Baghdad
Solid Tumor, MET Alteration
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.
- Trial name
- NCT06669117
- Testing
- VERT-002
- Where
- 19 sites in United States, Belgium and 7 more
- Volunteers
- 140 people
- Sponsor
- Pierre Fabre Medicament
Colorectal Cancer
"High Levels of EMT-TFs for the Diagnosis of Colorectal Cancer (CRC)"
The present study is aimed at detecting and measuring mRNA levels of genes involved in epithelial to mesenchymal transition (EMT) in biological samples, i.e.
- Trial name
- NCT04323813
- Testing
- Liquid biopsy
- Where
- Italy
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
Chronic Periodontitis
Identification of EMT Indicators in Healthy and Periodontally Diseased Gingival Samples
The current study focuses on the localization and quantitative assessment of growth factors and cytokines related to the EMT process found in the human gingival tissue samples taken from periodontally diseased individuals…
- Trial name
- NCT03462953
- Testing
- Gingival tissue samples will be harvested
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Cairo University
Non-Small Cell Lung Cancer
Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung…
- Trial name
- NCT02544633
- Testing
- MGCD265
- Where
- 94 sites in United States, Australia and 7 more
- Volunteers
- 68 people
- Sponsor
- Mirati Therapeutics Inc.
Prostate Cancer, Metastatic Cancer
CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.
Identification of biomarkers (Circulating Tumor Cells (CTC), free DNA, Stem Cells and EMT-related antigens) that may be predictive of outcome of activity of cabazitaxel treatment in castration-resistant prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Cancer, Castration-resistant Prostate Cancer, Circulating Tumor Cells
- Trial name
- IRSTB030 (NCT03381326)
- Testing
- blood and FFPE sample collection
- Where
- 9 sites in Italy
- Volunteers
- 104 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Peritoneal Dialysis Complication
EMT in Peritoneal Dialysis Patients
Approximately 10-11% of end stage kidney disease patients worldwide utilize peritoneal dialysis (PD) as their method of renal replacement therapy.
- Trial name
- NCT03458819
- Testing
- Isolation of peritoneal mesothelial cells
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Colorado, Denver
Neoplasms
OMO-1 in Solid Malignancies
This is a modular, first time in patient, open-label, multicentre study of OMO-1, administered orally, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid…
- Trial name
- NCT03138083
- Testing
- OMO-1
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 40 people
- Sponsor
- Octimet Oncology N.V.
Breast Cancer, Ovarian Cancer
Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive System
The study evaluates the level and molecular profiles of different CTC populations as markers for predicting the risk of developing hematogenous metastases and the effectiveness of treatment in patients with tumors of the female…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer
- Trial name
- CTCs (NCT04817501)
- Testing
- Taking 5 ml of venous blood at different time intervals, Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any
- Where
- Russia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Breast Cancer, Lymph Node Metastases
Role of SIRT1 in Regulation of Epithelial-to-mesenchymal Transition in Breast Cancer Lymph Nodes Metastasis
Luminal A breast cancer is a kind of breast cancer with low rate lymph node metastasis and good survival. But in clinical practice, Luminal A breast cancer can present with early, unexpected lymph node metastasis some time…
- Trial name
- NCT04137406
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Peking University People's Hospital
NSCLC
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093.
- Trial name
- NCT04077099
- Testing
- REGN5093
- Where
- 29 sites in United States, France and 1 more
- Volunteers
- 95 people
- Sponsor
- Regeneron Pharmaceuticals
Neoplasms, Neoplasm Metastasis
A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors
- Conditions
- Neoplasms, Neoplasm Metastasis, Non-Small-Cell Lung Cancer
- Trial name
- NCT03797391
- Testing
- EMB-01
- Where
- 5 sites in United States, China
- Volunteers
- 186 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Urothelial Bladder Carcinoma, Bladder Carcinoma
Tumor Budding and T1 Substaging in Urothelial Bladder Cancer
Bladder cancer is a significant global and local health concern, and predicting how aggressive a patient's tumor will behave is critical for guiding treatment.
- Conditions
- Urothelial Bladder Carcinoma, Bladder Carcinoma, Non-Muscle-Invasive Bladder Cancer (NMIBC), Muscle-Invasive Bladder Cancer (MIBC)
- Trial name
- NCT07529639
- Volunteers
- 100 people
- Sponsor
- Assiut University
Solid Tumor, Metastatic Cancer
Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy
This is a Phase 1 clinical study to investigate the safety, pharmacokinetics and pharmacodynamics of AB-16B5 in patients with an advanced solid malignancy.
- Trial name
- NCT02412462
- Testing
- AB-16B5
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Alethia Biotherapeutics
Solid Tumors
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
This is a randomized, placebo-controlled, double-blind, 3-way crossover phase I study being conducted on healthy volunteers to investigate the effect of single dose of AZD6094 (600 mg) on cardiac repolarization under…
- Trial name
- NCT03258515
- Testing
- AZD6094 200 mg, Moxifloxacin
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AstraZeneca